MAAT MaaT Pharma SA

EPA · FR · Healthcare · Biotechnology · maatpharma.com

0.9390EUR-7.03%Mkt Cap: 19.21M $P/E: —Today

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in p…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap19.21M USD

Enterprise Value—

Revenue (TTM)3.45M USD

Gross Profit3.40M USD

Net Income (TTM)-33.76M USD

Revenue/Share0.28 EUR

Last Price0.9390 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees52

CountryFR

SectorHealthcare

IndustryBiotechnology

ISINFR0012634822

Valuation

P/E (Trailing)—

P/E (Forward)-0.91

PEG—

EV/EBITDA—

EV/Revenue—

P/S5.98

P/B10.52

EPS (TTM)-1.90

EPS (Forward)-1.11

52W Range

0.91600% of range8.620

52W High8.620 EUR

52W Low0.9160 EUR

Profitability

Gross Margin69.05%

Oper. Margin-1761.26%

EBITDA Margin0.00%

Profit Margin-686.58%

ROE-1726.57%

ROA-69.72%

Growth

Revenue Growth-55.50%

Earnings Growth—

Cash Flow & Leverage

Operating CF-17.08M USD

CapEx (TTM)660.87K USD

FCF Margin—

FCF Yield—

Net Debt—

Net Debt/EBITDA—

Balance Sheet

Debt/Equity8.56

Current Ratio—

Quick Ratio—

Book Value/Sh0.10 EUR

Cash/Share—

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating2.0 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)6.500 EUR

Upside (mean)+592.2%

Target Range3.000 EUR – 10.00 EUR

3.000+592.2% to mean10.00

# Analysts2

Ownership

Shares Out.18.82M

Float11.04M

Insiders22.06%

Institutions46.64%

Technical

SMA 502.444 (-61.6%)

SMA 2004.514 (-79.2%)

Beta0.41

S&P 52W Chg14.58%

Avg Vol (30d)133.09K

Avg Vol (10d)164.83K

Technical Indicators

RSI (14)29.1

MACD-0.4566

MACD Signal-0.4171

MACD Hist.-0.0395

BB Upper3.155 EUR

BB Middle1.720 EUR

BB Lower0.2851 EUR

BB Width166.85%

ATR (14)0.2176 EUR

Vol Ratio (20d)0.89x